Terms: = Ovarian cancer AND CD79A, ENSG00000105369, 973, P11912, MB-1, IGA AND Treatment
21 results:
1. Linear iga bullous dermatosis associated with immunotherapy.
Momin B; Nguyen TF; Glade D; Messer A
Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478666
[TBL] [Abstract] [Full Text] [Related]
2. Targeting intracellular oncoproteins with dimeric iga promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers.
Biswas S; Mandal G; Anadon CM; Chaurio RA; Lopez-Bailon LU; Nagy MZ; Mine JA; Hänggi K; Sprenger KB; Innamarato P; Harro CM; Powers JJ; Johnson J; Fang B; Eysha M; Nan X; Li R; Perez BA; Curiel TJ; Yu X; Rodriguez PC; Conejo-Garcia JR
Immunity; 2023 Nov; 56(11):2570-2583.e6. PubMed ID: 37909039
[TBL] [Abstract] [Full Text] [Related]
3. Nurse-led exercise and cognitive-behavioral care against nurse-led usual care between and after chemotherapy cycles in Han Chinese women of ovarian cancer with moderate to severe levels of cancer-related fatigue: A retrospective analysis of the effectiveness.
Yang W; Xi J; Guo L; Cao Z
Medicine (Baltimore); 2021 Nov; 100(44):e27317. PubMed ID: 34871205
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of safety and efficacy of apatinib combination with chemotherapy for ovarian cancer treatment: a systematic review and meta-analysis.
Qi J; Liu E; Yue H; Chen G; Liu Y; Chen J
Ann Palliat Med; 2021 Sep; 10(9):9902-9913. PubMed ID: 34551570
[TBL] [Abstract] [Full Text] [Related]
5. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of ovarian cancer.
Jiao J; Jiang L; Luo Y
Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
[TBL] [Abstract] [Full Text] [Related]
6. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M; Imoto S; Ishida T; Ito Y; Iwata H; Masuda N; Mukai H; Saji S; Shimizu A; Ikeda T; Haga H; Saeki T; Aogi K; Sugie T; Ueno T; Kinoshita T; Kai Y; Kitada M; Sato Y; Jimbo K; Sato N; Ishiguro H; Takada M; Ohashi Y; Ohno S
Lancet Oncol; 2021 Jan; 22(1):74-84. PubMed ID: 33387497
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathologic characteristics of recurrent endometrioid endometrial cancer patients and analysis of methods used durıing surveillance.
Simsek SY; Serbetcioglu G; Alemdaroglu S; Yetkinel S; Durdag GD; Celik H
J Gynecol Obstet Hum Reprod; 2019 Sep; 48(7):473-477. PubMed ID: 31212025
[TBL] [Abstract] [Full Text] [Related]
8. Hyper IgM Syndrome: a Report from the USIDNET Registry.
Leven EA; Maffucci P; Ochs HD; Scholl PR; Buckley RH; Fuleihan RL; Geha RS; Cunningham CK; Bonilla FA; Conley ME; Ferdman RM; Hernandez-Trujillo V; Puck JM; Sullivan K; Secord EA; Ramesh M; Cunningham-Rundles C
J Clin Immunol; 2016 Jul; 36(5):490-501. PubMed ID: 27189378
[TBL] [Abstract] [Full Text] [Related]
9. cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.
De Angelis R; Sant M; Coleman MP; Francisci S; Baili P; Pierannunzio D; Trama A; Visser O; Brenner H; Ardanaz E; Bielska-Lasota M; Engholm G; Nennecke A; Siesling S; Berrino F; Capocaccia R;
Lancet Oncol; 2014 Jan; 15(1):23-34. PubMed ID: 24314615
[TBL] [Abstract] [Full Text] [Related]
10. [Endometrioid endometrial cancer--the prognostic value of selected clinical and pathological parameters].
Gottwald L; Chałubińska J; Moszyńska-Zielińska M; Piekarski J; Tyliński W; Szwalski J; Kubiak R; Pasz-Walczak G; Hendzel K; Ciałkowska-Rysz A
Ginekol Pol; 2011 Oct; 82(10):743-8. PubMed ID: 22379937
[TBL] [Abstract] [Full Text] [Related]
11. A prospective, randomized trial of integrative medicine for women with ovarian cancer.
Judson PL; Dickson EL; Argenta PA; Xiong Y; Geller MA; Carson LF; Ghebre R; Jonson AL; Downs LS
Gynecol Oncol; 2011 Nov; 123(2):346-50. PubMed ID: 21864886
[TBL] [Abstract] [Full Text] [Related]
12. [Various acute phase reactants in different types of proliferative diseases of the uterine appendages].
Zorina VN; Kozlov IG; Tret'iakova TV; Promzeleva NV; Bazhenova LG; Zorina RM; Riabicheva TG; Zorin NA
Klin Lab Diagn; 2009 Oct; (10):16-9. PubMed ID: 20000108
[TBL] [Abstract] [Full Text] [Related]
13. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Havrilesky LJ; Secord AA; Darcy KM; Armstrong DK; Kulasingam S;
J Clin Oncol; 2008 Sep; 26(25):4144-50. PubMed ID: 18757328
[TBL] [Abstract] [Full Text] [Related]
14. Determination of antiovarian antibodies after laparoscopic ovarian electrocauterization in patients with polycystic ovary syndrome.
Alborzi S; Tavazoo F; Dehaghani AS; Ghaderi A; Alborzi S; Alborzi M
Fertil Steril; 2009 Apr; 91(4):1159-63. PubMed ID: 18439597
[TBL] [Abstract] [Full Text] [Related]
15. [Chemotherapeutic drugs enhanced rsTRAIL tumoricidal activity].
Wang MJ; Liu YX; Li XL; Shi J; Liu SL; Zheng DX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Oct; 26(5):524-8. PubMed ID: 15562765
[TBL] [Abstract] [Full Text] [Related]
16. [Heat shock proteins and malignancies of the female genital tract].
Piura B; Rabinovich A; Yavelsky V; Wolfson M
Harefuah; 2002 Nov; 141(11):969-72, 1010, 1009. PubMed ID: 12476632
[TBL] [Abstract] [Full Text] [Related]
17. iga antibodies to the 27-kDa heat-shock protein in the genital tracts of women with gynecologic cancers.
Korneeva I; Bongiovanni AM; Girotra M; Caputo TA; Witkin SS
Int J Cancer; 2000 Sep; 87(6):824-8. PubMed ID: 10956393
[TBL] [Abstract] [Full Text] [Related]
18. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.
MacLean GD; Bowen-Yacyshyn MB; Samuel J; Meikle A; Stuart G; Nation J; Poppema S; Jerry M; Koganty R; Wong T
J Immunother (1991); 1992 May; 11(4):292-305. PubMed ID: 1599915
[TBL] [Abstract] [Full Text] [Related]
19. Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modifications.
Mattes MJ
J Natl Cancer Inst; 1987 Oct; 79(4):855-63. PubMed ID: 2443739
[TBL] [Abstract] [Full Text] [Related]
20. Metastatic adeno or undifferentiated carcinoma from an unknown primary site--natural history and guidelines for identification of treatable subsets.
Kirsten F; Chi CH; Leary JA; Ng AB; Hedley DW; Tattersall MH
Q J Med; 1987 Feb; 62(238):143-61. PubMed ID: 3659256
[TBL] [Abstract] [Full Text] [Related]
[Next]
